December 10, 2020: We need longer-term data on the Pfizer COVID-19 vaccine to fully understand if benefits outweigh the risks for frail patients and all races/ethnicities, and for everyone else as well. It is essential that FDA ensure the continuation of the randomized controlled trial.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR’s Public Comments on Breast Cancer Treatment for Premenopausal Women
December 7, 2020: We strongly recommend that clinical trials on breast cancer treatments should include pre-menopausal women.
Read More »Public Comments Regarding ACIP Meeting on December 1, 2020
December 1, 2020: We are concerned about the lack of data on the vaccines in patients living in long-term care facilities, or any patients over 65 years of age.
Read More »NCHR’s Comments on Colorectal Cancer Screening in Asymptomatic Adults
November 23, 2020. We support for the United States Preventive Services Task Force’s (USPSTF) draft recommendation statement regarding colorectal cancer screening in asymptomatic adults.
Read More »NCHR’s Comments on Drug Labeling for Geriatric Patients
November 16, 2020: We agree that the FDA should immediately develop clear guidelines for labeling that addresses safety and effectiveness of drugs in the geriatric population.
Read More »